Present Your Research at RDD 2026

The Poster Session at RDD 2026 presents research on all aspects of pulmonary and nasal delivery. Posters will be presented in Phoenix, Arizona, as a traditional poster augmented by a ten-minute recorded presentation for on-demand viewing.
The abstract submission deadline is January 23, 2026.
Accepted abstracts will be published in the Conference Proceedings available to all conference delegates, and those from graduate students will be automatically eligible for the VCU RDD Peter R. Byron Graduate Student Award. The award covers registration fee, travel expenses and accommodation up to a maximum of $2000.
Posters on the Podium will showcase editor-selected posters during a series of ten-minute presentations in the main auditorium followed by a fast-paced Q&A session. All poster abstracts and on-demand presentations will be featured in online Knowledge Spaces.
Registration fees will be waived for graduate students (no more than 2 per advisor) with an accepted poster abstract if their academic advisor is registered to attend at the discounted academic rate of $995. It is expected that the graduate student (not their academic or industrial advisor) will present the poster in Arizona. By waiving the registration fee, we hope to encourage young scientists to attend RDD, where they'll receive expert feedback on their work, hear the latest from opinion leaders, and network with peers, collaborators and future employers.
When and Where?
Posters will be continuously accessible to delegates from 10:00 AM until 7:00 PM on Monday, May 11, and from 8:30 AM to 7:00 PM on Tuesday, May 12, in the Kierland Ballroom. The Poster and Exhibition Session will be the only RDD event during the following times:
- Monday, May 11, 11:30 AM–2:30 PM and 5:00–7:00 PM
- Tuesday, May 12, 11:30 AM–2:30 PM and 5:00–7:00 PM
Posters, exhibit tables, lunch and refreshment breaks will share an expansive space to maximize interactivity.
Submit your Poster Abstract
Poster Presentations
Amiko
Martijn F. Grinovero
Improvement In Inhalation Technique During A Pharmacy-led Connected Inhaler Service Evaluation In Adults With Asthma Or COPDGoncalo Farias
Evaluation Of Regional Deposition In 3D Printed Infant Nasal Cast Models For Vaccination via Intranasal DeliveryGoncalo Farias
Human Factor Studies and Actuation Force in Multidose Nasal Pumps Sana Hosseini
From Droplets To Particles: Excipients Shaping Spray‑dried Intranasal PowdersSana Hosseini
Scalable Spray Drying Framework For Intranasal Powders Across Multiple Sites And Dryer ScalesBenjamin Thorne
Simulating In Vitro Aerosolization Performance: A Tool To Support Valve Selection For Suspension pMDI ProductsShaun Williams
Decarbonizing The pMDI Valve: Designing A Low-carbon Valve For The Next Generation Of pMDIsCambridge Healthcare Innovations
Jamie Greenwood
In Vitro Performance Of A Mannitol-based Spray Dried Powder Combined With Quattrii Carrier Free Dry Powder InhalerCroda
Veronica Freitas Blanco
Evaluation of Permeation Enhancers for Intranasal Delivery of Epinephrine and Naloxone Hydrochloride Using a 3D Nasal Tissue ModelEastern Institute of Technology
Tingting Shi
Development And Characterization Of Inhalable Microparticles Co-delivering Nintedanib And Metformin For Idiopathic Pulmonary FibrosisDimitris Spaneas
Minimizing Variability In Shot Weight Of HFO-1234ze(E) MDIs Using Automated Systems And Comparing To Manual HandlingNavid Monshi Tousi
In Silico Evaluation Of Nasal Spray Plume Angle And Ovality On Regional Nasal DepositionHosein Sadafi
Using Rapid Deposition Analysis And rAPSD Variability To Support In Silico Bioequivalence AssessmentIrene Rossi
In Vitro Performance Assessment Of Fluticasone Propionate/salmeterol Xinafoate Blends Developed For A Capsule-based DeviceHealthy Airways
Loy Britto
Evaluation Of Albuterol Sulfate Formulations With Low GWP Propellants Using A Non-PFAS Coated MDI CanAngelo Araujo
Advancing Nasal Powder Delivery: A Structured Evolution Of Device PerformanceClaudia Costa
β-lactoglobulin (Dispersome®) As A Next-gen High-performance Excipient For Pulmonary and Nasal DeliveryBeatriz Gamelas
Setting Quality Attributes Of Air-liquid Interface Cultures Modeling Distinct Respiratory Tract Regions To Assess Dry Powder Formulation PermeabilityInformiX Pharma
Parmesh Gajjar
Determining Material Composition Of Fines-only Formulations Through X-ray Computed TomographyEF
Inhalon Biopharma
Ellen Farmer
Stability And Aerosol Characterization Of ACE-2 Decoy Antibody Using A Vibrating Mesh NebulizerRodrigo Amorim
A Call To Action For Global Pandemic Readiness: Mucosal Immunity And Temperature-stable Respiratory VaccinesSvetlana Lyapustina
Managing Supply Continuity During The pMDI Transition To Next Generation PropellantsJohannes Gutenberg-Universität Mainz
Moritz Fleischhauer
Single Jet Impaction As An Alternative Mechanism For Soft Mist GenerationDonovan Yeates
Universalization Of The AeroPulsR’s High-concentration Aerosol Delivery Platform From Respiratory Human Critical Care To Animal HealthcareRM
Rob McCorkle
Tuning Nasal Spray Performance By Formulation DesignKP
Katherine Polzin
Assessment Of Dissolution Profiles For Mometasone Furoate Inhalers Using A Paddle Over Disk Dissolution ApparatusKeith Ung
Design Of Spray Dried GLP-1 Exenatide Microparticles For Pulmonary Delivery: A Room-temperature Stable Formulation Of An Oxidation Sensitive PeptideKeith Ung
Recording And Analysis Of Healthy Subjects Breathing Maneuvers With An Adheresp Breath-actuated NebulizerKL
Ken Lo
Powder Rheology For Batch Comparison During ManufacturingMichael Shultz
Excipient Effects On Spray-dried Antibody Stability: A Comparative StudyRui Alberto Teixeira Cruz
Optimization Of Capsule-filling Process Parameters In The Development Spray Dried Powders For Pulmonary DeliveryXL
Luxena Pharmaceuticals
Xiaodong Li
Ondansetron Inhalation Powder – Bioavailability And Safety Results From Phase I Clinical StudyVaishnavi Kapileshwari
Understanding Morphological Aspects Of API And Excipient Particles In DPI FormulationsMonash University
Edward Attenborough
Medium Chain Length Polyhydroxyalkanoate Nanoparticles For Controlled Drug Delivery To The LungBM
Ben Miles
Predicting Nasal Deposition From Minimal In Vitro Data With Machine LearningNitto BioPharma
Chun Yang
Inhalation and Systemic Delivery of mRNA to the Lung using a Stable Lipid Nanoparticle PlatformOrexo AB
Jonas Sävmarker
Thermostable Powder-based Nasal Vaccine: Preclinical Evaluation Of Immunogenicity And StabilityDavid Lewis
Defining “immediate” Actuation In Suspension pMDIs: Acoustic, Gravimetric And Delivered Dose Characterisation Of Shake–fire TimingMA
Murat Ali
Development Of The Open-Inhale-Close (OIC) Device With Connectivity For Patient-centric And Non-intrusive Dry Powder DeliveryCarolina Dantas
APEX: Predicting Pulmonary Drug Deposition Using Real Time Connected Inhalation DataResyca
Nicolas Buchmann
Actuation And Viscosity Dependent Aerosol Generation In Nasal Sprays: A Mechanistic Comparison Of Swirl Nozzle And Soft Mist TechnologiesRTI International
Sara Maloney Norcross
Replacing Sugar Excipient With Polymyxins To Improve Dosing Of A Dry Powder Teixobactin-lipopeptide Hybrid For The Treatment Of Pulmonary InfectionsEP
RTI International
Erik Pena
Optimization Of Spray-dried Spectinamide Lee1810 Inhalation PowdersScientific Consultant
Stephen Stein
A Simple Calculation To Provide Insight Into Impact Of Propellant On Spray PatternErik Boldt
Antimicrobial Effectiveness Testing Of HFO-1234ze(E) With And Without EthanolGregory Smith
Performance Assessment Of Budesonide Solution Formulations In HFO-1234ze(E) To A Reference Listed DrugGregory Smith
Performance Assessment Of Fluticasone Propionate Suspension Formulations In HFO-1234ze(E) To A Reference Listed Drug.Yannick Baschung
Adapting Standard Nasal Spray Testing Methodologies For Live BSL-2 Viral Products: An In-use Case Study With A SARS-CoV-2 Nasal VaccineSouth Dakota State University
Joshua Reineke
Characterization And Safety Of Biomimetic MOFs In The Raw 264.7 Cell LineSouth Dakota State University
Joshua Reineke
Numerical And Experimental Studies To Enhance Nasopharyngeal Deposition By Optimizing Intranasal Drug Delivery ParametersPK
St. John's University
Parasharamulu Kommarajula
Development And Evaluation Of Inhalable Imipenem Dry Powder For Treating Pulmonary Pseudomonas Aeruginosa InfectionsAnna Vivani
Preliminary Spray Drying Screening Study For The Reformulation Of Ganaxolone From Oral To Nasal DeliveryThe University of Alabama at Birmingham
Teri Ross
Particle Level Assessment Of Morphology And Composition As A Function Of Aerosol Particle Size Using Optical Photothermal Infrared Microscopy: Comparison Of Fluticasone/salmeterol/lactose In Advair Diskus And Wixela InhubMark Nagel
Can A Mixing Inlet Interposed Between A Pressurized Metered Dose Inhaler-spacer Combination And Cascade Impactor Enable Effective Performance Testing At Widely Different Inhalation Flow Rates?U.S. Food & Drug Administration
Ju Du
Analysis Of Hold Time Review For Metered Dose Inhaler Drug ProductsU.S. Food & Drug Administration
Bora Sul
Computational Modeling Of Actuation Timing Effects On Regional Lung Drug Delivery From Pressurized Metered-dose InhalersU.S. Food & Drug Administration
Yang Yang
Comparative Analysis Of Phospholipid Porous Particle Size Distribution In Orally Inhaled Drug Products - In Vitro And In Silico ApproachesUnited Arab Emirates University
Adel Hashish
Charge-assisted Aerosol Deposition In Lung AirwaysUniversity of Bristol
Anna Catton
Rapid Stability Modelling as a Predictor for Long-term Standard Stability TestingUniversity of Bristol
Sorrel Haughton
Influence of Formulation Viscosity and Surface Tension on Spray Formation and Nasal Deposition with a VP7 Nasal Valve DeviceUniversity of Hertfordshire
Hessam Rasooli Nia
Nasal Delivery Of Liquid Medicines: Effect Of Viscosity And Polymer Structure On Delivery Performance.University of Michigan
Grace Xia
A Distribution-based Metric For Quantifying Dispersibility In Dry Powder InhalersYX
University of Michigan
You Xu
Inhalable Anti-inflammatory psLNPs Enable Mucus Penetration and circRNA CFTR Delivery For Cystic Fibrosis TherapyUniversity of Michigan
Guizhi (Julian) Zhu
Airway Delivery Of CircRNA Using Pulmonary-surfactant-coated Lipid Nanoparticles For Cystic Fibrosis Gene TherapyUniversity of Oklahoma
Lucila Garcia-Contreras
Direct Aerosol Administration In Preclinical Respiratory Models: Influence Of The Parameters Of Administration Using The Fine Mist SprayerFrancesca Buttini
Design And Stability Evaluation Of An Inhalable Pegylated Pramlintide Dry PowderFrancesca Buttini
Engineering Budesonide Microparticles to Improve Suspension Stability in Low- GWP pMDIs University of Sydney
Zhengqi Xu
Combination Of A Newly Developed Modified Next Generation Impactor (mNGI) And Franz Cell Method For In Vitro Dissolution Characterization Of Inhalation Powders: Development And ValidationUniversity of Sydney
Zhengqi Xu
Modified Next Generation Impactor (mNGI) And Franz Cell For Characterization Of The In Vitro Dissolution Performances Between Innovator And Generic Dry Powder InhalersJordan Potts
Influence Of L-leucine Content On The Internal And External Morphology Of Spray Dried ParticlesFederica Carnamucio
Inhalable Liposomal Combination Therapy For The Treatment Of Osteosarcoma Lung MetastasesBaiwei Chen
Impact Of Spray Dryers With Distinct Working Principles On The Aerosol Performance And Physicochemical Properties Of Synthetic Dipalmitoylphosphatidylcholine (DPPC) Dry Powder FormulationsCaleb Dalton
Investigating Effects Of Single Prong Nasal Interface Orifice Diameter And Capillary-to-orifice Distance On AJ-DPI Plume Properties And PerformanceVictoria Garcia
Studying The Pharmacodynamic Response Of The Tumor Immune Microenvironment In Osteosarcoma Lung Metastases Following Locally Administered Gemcitabine ChemotherapyMH
Mohammad Hejazi
Device Characteristics And Orientation Effects On Regional Nasal Drug Deposition In An Anatomical Nasal ModelMH
Mohammad Hejazi
Effect Of Breathing Pattern And Emitted Dose On Regional Deposition Of Soft-mist Nasal SpraysMohammad Momin
Achieving Improved Lung Delivery Of Synthetic Lung Surfactant Excipient Enhanced Growth (SLS-EEG) Dry Powder Aerosol Formulations In NeonatesRudra Pangeni
Tobramycin SLS EEG Dry Powder Formulation For Treating Pseudomonas Aeruginosa-induced Lung Infection In RatsSurendra Poudel
Pegylated Ciprofloxacin Liposomal Dry Powder: Efficacy In Acute Rat Pseudomonas Aeruginosa Induced Lung InfectionCimone Richardson
Pulmonary Delivery Of Ginkgetin Attenuates Lung Fibrosis In A Rat ModelRiley Schweizer
Development Of A New Inhalation Assisted DPI (IA-DPI) And SLS-EEG Platform For Administering Anti-infective Aerosols To ChildrenLaura Vargas
Development And Validation Of A Customizable Neonatal Breathing Simulator For Aerosol Delivery Evaluation: A Case Study Using A Laryngeal Mask Airway Aerosol Delivery System (LMA-ADS)Western University
Ziyi Fan
Inhaler Usage Recognition Using Transformer-based Acoustic ModelingWoolcock Institute of Medical Research
Patrick He
Bridging Deposition And Permeation: Evaluation Of Intranasal Dry Powder Antiemetic FormulationsDean Wang
Nebulization Of Complex Formulations : A Physicochemical Property Tailored Strategy For Vibrating Mesh Nebulizers
Poster Abstract and Submission Instructions
We strive to publish impactful, scientifically accurate high-quality abstracts. Those with a high chance of acceptance:
- Describe recent, relevant experiments, innovations and insights
- Include data or outline groundbreaking concepts or approaches
- Support claims and conclusions with data or references, especially those making comparisons to competing commercial products
- Use scientific language understandable by researchers in the field
- Have not been presented at other conferences
Three- to five-page poster abstracts should be submitted in Microsoft Word. Use double-spaced Arial 12-point font. Please follow instructions in the Poster Abstract Instructions and share these with any colleagues or third-party vendors who are assisting you.
The Publication Process
- You must submit your poster abstract using the web portal before January 23, 2026.
- A reviewer will evaluate your submitted poster abstract and communicate a decision to the primary author before March 6, 2026. Reviewers may accept, reject or request modifications. Corrections must be made within 5 days.
- You must obtain and send us permission from the original publisher to include previously published materials in your poster abstract. Permission should be sent to info@rddonline.com. Most publishers have their own process to request permission but if not, please use our Copyright Permission Request Form.
- Your reviewer will accept or reject your final abstract before March 30, 2026.
- You must E-mail a signed Copyright Transfer Form (as a PDF) to info@rddonline.com by March 30, 2026 so we can publish your work. Authors retain the right to use the content of their articles as they see fit, including extending their work into manuscripts submitted to journals. The Copyright Transfer Form gives RDD ownership of the final typeset abstract. We grant complimentary permission to use tables, figures and verbatim quotations in journal articles in exchange for acknowledgement that RDD was the original publisher.
- The publisher will typeset your abstract and email you PDF proofs to review and correct. You should return the proofs by email within 48 hours of receipt. Please only make typographical corrections at this stage.
- Questions about the publication process should be sent to Richard Dalby, University of Maryland.
Preparing and Displaying a Poster
Posters give you the opportunity to display innovative research and technology and interact face-to-face with conference delegates. You are also strongly encouraged to prepare an on-demand recorded presentation to share your work with all delegates. These will be posted in the appropriate online Knowledge Space through June 30 (see On-Demand Narrated Presentation Guidelines below). Taking this extra step allows all delegates to ask you questions using Messaging and means you are ready if invited to participate in Posters on the Podium.
Maximum size of your poster is 45 inches (1.1 meters) tall and 90 inches (2.2 meters) wide. Designs using text and easily interpreted, eye-catching graphics readable from 6 feet (1.8 meters) garner most attention. Focus on one or two themes and keep the design simple to emphasize your main findings. There’s no need to include a lot of background information.
Poster content must be closely related to your published abstract with all claims and conclusions supported by data or references. Do not include wildly speculative or unsubstantiated comments.
We will provide supplies to mount your posters on a board. A skirted, 15-inch (0.4 meter)-wide table beneath your poster will allow distribution of copies of your poster and other literature. It also facilitates demonstrations of small handheld devices or use of a laptop, but is unsuitable for anything heavier than 10 lbs. Posters do not have access to electricity.
Please be present at your poster to answer questions for at least an hour each time the dedicated Poster and Exhibition is scheduled. If you do not intend to stay the whole time, it is helpful to display a sign showing when you will be present. Messaging will also be available via the Conference website to encourage discussion with delegates.
If you need to ship your poster rather than hand-carry, see Shipping Instructions below.
Poster Set-up and Take-down
- Set-up is encouraged on Sunday, May 10, between 3:00 PM to 7:00 PM. Please register at the Registration Desk on the lobby level of the conference hotel and immediately proceed to the Kierland Grand Ballroom. Our staff will direct you to your table location. Do not set up in a different location. Late arrivals may set up on Monday, May 11, from 7:30 to 9:00 AM.
- To protect your property, hotel security will not allow access to the Poster and Exhibition area from Sunday at 7:00 PM until Monday at 7:30 AM. We recommend that you take small, high-value items such as laptops and prototype devices with you when you are not at your poster or when leaving the space for the evening.
- A Poster and Exhibition Floor Plan will be provided to all registrants.
- Posters must be removed at 7:00 PM on Tuesday, May 12.
Disclaimer
The meeting organizers and the Westin Kierland expressly disclaim responsibility for loss or damage to any items you bring into the Poster and Exhibition space.
On-Demand Narrated Presentation Instructions for All Presenters - Due April 13, 2026
We ask poster presenters to create a compelling 10-minute narrated slide presentation that will be posted on the Conference website and visible to all delegates through June 30. The RDD audience is familiar with many aspects of nasal and pulmonary delivery so keep the background short. Focus on clearly presenting data and conclusions in your abstract. Ensure all claims, especially those that mention competitors, are supported by data or references. Do not include wildly speculative or unsubstantiated comments.
Approximately 8 slides should first be prepared using PowerPoint before using the recording function to add your voice-over narration (do not include video). Presentations that exceed 10 minutes may end abruptly once posted on our platform. Practice your timing before making your final recording.
We offer the following as a guide:
Slide Count
- 1 Slide: Shows your presentation title (exactly the same as your poster abstract), names of all presenters and their institution(s). Optionally, include contact information and the presenter's photo. Please note that you are consenting to this information being visible to delegates on all RDD websites when you send us your slides
- 1 Slide: Background / Introduction
- 1 or 2 Slides: Methods
- 3 or 4 Slides: Data / Conclusions
Slide Preparation
- Prepare your slides in 16 X 9 format.
- Some delegates will be viewing your slides on a small screen. Don’t allow busy slides, small fonts, complex backgrounds and institutional logos to diminish your message.
- Figures and photographs should be clearly visible.
- Ensure the axes on graphs are clearly labeled and that highly visible lines or symbols differentiate among data sets. Provide a key. Do not include graphic elements you will not discuss in the text.
Voice-over Narration
Adding your voice-over narration is easy. This How-To-Video supplements the summary below.
- Prepare to record in a quiet location.
- Open your presentation and click the Slide Show tab.
- Check that your microphone is set up correctly. A headset microphone often produces the best quality audio.
- Select the slide where you want the recording to begin, then click Record Slide Show and start talking.
- Click End Show to stop recording.
- A Save dialog box appears. Click Yes to save your recording, or No if you want to record it again. Saving overwrites anything you've previously recorded. It is possible to re-record individual slides.
- Click Play from Start to review your recording.
Submit Your File
Send your final PowerPoint (.pptx) file to info@rddonline.com before April 13, 2026.
Send your final PowerPoint (.pptx) file
If the file is too large to e-mail, your organization may have a preferred file transfer protocol (FTP), but if not, we recommend using wetransfer.com.
Questions?
For further information, contact Richard Dalby.